RJM Group

What RJM Group does

RJM Group is a privately held, for-profit consulting firm headquartered in South Easton, United States, that delivers health economics and outcomes research (HEOR) and outcomes-information services to pharmaceutical industry clients. The firm's positioning is narrowly specialized: rather than spanning the broader life-sciences consulting spectrum, RJM Group's stated value proposition sits in the HEOR and evidence-information layer that supports pricing, reimbursement, payer engagement, and value-communication decisions for drug manufacturers.

Operationally, the company operates as a boutique consultancy with 11-50 employees, which places it firmly in the small/mid-sized advisory segment. The firm does not disclose a packaged product platform, proprietary technology stack, software licenses, API integrations, or AI/ML capabilities in the available data. Its operating model is therefore consistent with a classic professional-services construct — expert time sold against client engagements in HEOR. No pricing model, fee schedule, retainer terms, hourly rates, or project-based pricing benchmarks are publicly disclosed, and the firm's website (rjmgroupllc.com) returned only a loading/verification page during the source capture, providing no additional operational disclosure.

The data set is thin across most standard diligence dimensions: there are no disclosed funding rounds, ownership/parent-company information, management team bios, named customer logos, partnership announcements, awards, patents, regulatory actions, M&A activity, or financial metrics (revenue, growth rate, profitability). Geographic scope beyond the United States is not specified, and no subsidiaries, sub-brands, or previously-used trade names are reported. Investors should treat any inferences outside the core HEOR-consulting description as low-confidence.

Name

RJM Group

Website

https://rjmgroupllc.com

Company type

Private

Headcount range

11–50 employees

Short description

RJM Group is a privately held US consulting firm, based in South Easton, with 11-50 employees, that delivers health economics and outcomes research (HEOR) and outcomes-information advisory services to pharmaceutical industry clients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Consulting

NAICS

Management Consulting Services (54161), Other Management Consulting Services (541618), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN)

Keywords

• Health economics consulting
• Pharmaceutical consulting
• Outcomes research services
• Health economics outcomes
• Pharma market access

Headquarters

HQ city

South Easton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Core offering

RJM Group is a consulting firm that provides health economics and outcomes information to the pharmaceutical industry. The firm delivers HEOR advisory services that support pharmaceutical companies in evidence-based decision-making regarding healthcare interventions, pricing, and market access. Offerings are delivered as professional services rendered to pharma clients.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights2 records

Direct peers

• Cytel: Cytel provides biostatistics, HEOR, and real-world evidence services to pharmaceutical clients globally. It is a direct peer to RJM Group given its dedicated HEOR/RWE consulting practice serving similar pharma and biotech customers.
• Evidera: Evidera is a dedicated HEOR/RWE consulting firm (now part of Thermo Fisher's PPD) serving pharma and biotech. It is the most direct comparable to RJM Group given overlapping focus on health economics, outcomes research, and value evidence generation for pharmaceutical sponsors.
• Analysis Group: Analysis Group is a privately held economics and analytics consulting firm with a strong HEOR practice serving pharma and biotech. It is a direct peer to RJM Group given its boutique consulting model focused on health economics and outcomes research.
• OPEN Health: OPEN Health is a global health economics and outcomes research and market access consulting firm serving pharma clients. It is a direct peer given its specialized HEOR-focused boutique consulting model.
• Putnam Associates: Putnam Associates is a strategic consulting firm focused on pharma and biotech with HEOR and market access expertise. It is a direct peer given its boutique consulting model serving pharmaceutical clients with health economics and value evidence work.

Broad incumbents

• IQVIA: IQVIA is a global CRO and life sciences data/analytics leader with extensive HEOR/RWE capabilities serving pharma sponsors. It is a broad incumbent peer, competing with RJM Group on HEOR engagements while bundling clinical, commercial, and real-world data offerings.
• ICON plc: ICON plc is a leading global CRO offering HEOR and RWE services through its commercial and post-approval divisions. It is a broad incumbent peer given its comprehensive pharma services portfolio that overlaps with RJM Group's HEOR scope.
• Parexel International: Parexel is a global CRO with dedicated HEOR/RWE consulting capabilities serving pharmaceutical and biotech clients. As a broad incumbent, it competes with boutique HEOR firms like RJM Group on value evidence and market access projects.
• Syneos Health: Syneos Health (now part of Elliott/Veritas Capital) is a biopharmaceutical solutions organization offering clinical, commercial, and HEOR/RWE services. It is a broad incumbent peer given its pharma-focused service portfolio including outcomes research.
• Charles River Associates (CRA): CRA's Life Sciences practice provides HEOR, pricing, and market access consulting to pharma clients. It is a broad incumbent peer offering overlapping economics-based health consulting to pharmaceutical sponsors.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/rjm-group

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RJM Group